News

It is prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg. Oxsoralen-Ultra, in combination with a special type of phototherapy called PUVA (Psoralen plus UVA light) therapy,

The agreement expands Evotec’s drug discovery platform into the area of respiratory diseases through IR Pharma’s expertise in in vitro and in vivo Respiratory pharmacology. Under the alliance,

The $20MM facility will serve to expand Asymchem’s capabilities in high volume processing and back-end ingredient and intermediate production. The new facility will accommodate high volume processes and

As per the terms of the agreement, Arno will pay certain research, clinical and regulatory milestone payments as well as royalties on net sales of licensed products to

AFC is contributing to the Rx-360’s joint audit pilot program as the first US-based active pharmaceutical ingredient (API) manufacturer to be audited. AMPAC quality and regulatory affairs vice

The product was initially developed by BioSante and latter licensed to Teva for late stage clinical development, regulatory and marketing activities. BioSante is expected to receive royalties and

The study finds selective pharmacological inhibition of specific arms of the ß2AR signaling network to correlate the differential contribution of signaling events to specific components of the cell

The assay aids in the decision for repeat biopsy in men 50 years of age or older who have had one or more previous negative prostate biopsies The

The patent number 8,114,874 was entitled, Substituted Acetylenic Imidazo[1,2-B] Pyridazine Compounds as Kinase Inhibitors. The new patent covers both the compound itself and its pharmaceutical compositions. Additional patent